ReviewNature reviews. Disease primers2018
Multiple sclerosis.
Review in Nature reviews. Disease primers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 855 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Detection of STAT4 in Multiple Sclerotic Patients by Polymerase Chain Reaction and Flow Cytometry
Retinal Thickness as a Potential Biomarker of Neurodegeneration and Early Cognitive Impairment in Patients With Multiple Sclerosis
Who cites it
855 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,335 citations in OpenAlex.
- Higher disease reactivation risk in women after fingolimod withdrawal.Acta neuropathologica communications · 2026Pooled it
- Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.Journal of neurology · 2026Pooled it
- Long Non-Coding RNAs in Multiple Sclerosis-Differential Expression and Functional Implications.Genes · 2025Pooled it
- Pooled it
- Natalizumab for multiple sclerosis.The Cochrane database of systematic reviews · 2025Pooled it
- Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.Annals of neurology · 2026Trial
- Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.Journal of neurology · 2026Trial
- Trial
- Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.Journal of neurology · 2026Trial
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib and Effect on the QT/QTc Interval in Healthy Participants.Clinical and translational science · 2026Trial
- Contribution of structural and functional MRI in predicting response to motor training in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Trial
- Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.Journal of neurology · 2025Trial
- Trial
- Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Trial
- Capillary serum-based spectroscopic signature for multiple sclerosis: A novel diagnostic perspective.Practical laboratory medicine · 2026Article
- Association of HALP score with clinical and radiological activity following fingolimod discontinuation in patients with multiple sclerosis.eNeurologicalSci · 2026Article
- Association between CHI3L1 and CRTH2 genetic variants, clinical phenotype, and neurological disability in multiple sclerosis.Acta neurologica Belgica · 2026Article
- Neurogenic gastrointestinal, urinary, and sexual dysfunction in multiple sclerosis: a multidisciplinary framework for clinical practice.The Lancet regional health. Europe · 2026Review
- The dual role of arginine vasopressin in immune regulation: Balancing immunostimulation and immunosuppression.Brain, behavior, & immunity - health · 2026Review
- Targeting the HPGDS-PGDSignal transduction and targeted therapy · 2026Article
795 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. This disorder is a heterogeneous, multifactorial, immune-mediated disease that is influenced by both genetic and environmental factors. In most patients, reversible episodes of neurological dysfunction lasting several days or weeks characterize the initial stages of the disease (that is, clinically isolated syndrome and relapsing-remitting MS). Over time, irreversible clinical and cognitive deficits develop. A minority of patients have a progressive disease course from the onset. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, which can be associated with neuro-axonal damage. Focal lesions are thought to be caused by the infiltration of immune cells, including T cells, B cells and myeloid cells, into the central nervous system parenchyma, with associated injury. MS is associated with a substantial burden on society owing to the high cost of the available treatments and poorer employment prospects and job retention for patients and their caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.